Mirum Pharmaceuticals, Incyte Say Zilurgisertib Showed Meaningful Reductions in Heterotopic Ossification Lesion Volume During Clinical Trial

MT Newswires Live

06/15

Mirum Pharmaceuticals (MIRM) and Incyte (INCY) said Sunday their threapeutic candidate for fibrodysplasia ossificans progressiva, zilurgisertib, demonstrated positive results during a phase 2 study.

The product showed meaningful reductions in total heterotopic ossification, or HO, lesion volume and no new HO lesions and flare activity in adolescents and adults with fibrodysplasia ossificans progressiva.

The companies said the US Food and Drug Administration has accepted the new drug application and granted priority review for zilurgisertib as a treatment for fibrodysplasia ossificans progressiva in patients 12 years and older.

The Prescription Drug User Fee Act target date for the product is Sept. 26, according to the companies.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2643275959"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2643275959\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2643275959?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 16:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643275959","market":"sh","top_or_hot":-1,"title":"Mirum Pharmaceuticals, Incyte Say Zilurgisertib Showed Meaningful Reductions in Heterotopic Ossification Lesion Volume During Clinical Trial","media":"MT Newswires Live","content":"<html><body><p> Mirum Pharmaceuticals (MIRM) and Incyte (INCY) said Sunday their threapeutic candidate for fibrodysplasia ossificans progressiva, zilurgisertib, demonstrated positive results during a phase 2 study.</p><p>The product showed meaningful reductions in total heterotopic ossification, or HO, lesion volume and no new HO lesions and flare activity in adolescents and adults with fibrodysplasia ossificans progressiva.</p><p>The companies said the US Food and Drug Administration has accepted the new drug application and granted priority review for zilurgisertib as a treatment for fibrodysplasia ossificans progressiva in patients 12 years and older.</p><p>The Prescription Drug User Fee Act target date for the product is Sept. 26, according to the companies.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mirum Pharmaceuticals, Incyte Say Zilurgisertib Showed Meaningful Reductions in Heterotopic Ossification Lesion Volume During Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMirum Pharmaceuticals, Incyte Say Zilurgisertib Showed Meaningful Reductions in Heterotopic Ossification Lesion Volume During Clinical Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-15 16:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Mirum Pharmaceuticals (MIRM) and Incyte (INCY) said Sunday their threapeutic candidate for fibrodysplasia ossificans progressiva, zilurgisertib, demonstrated positive results during a phase 2 study.</p><p>The product showed meaningful reductions in total heterotopic ossification, or HO, lesion volume and no new HO lesions and flare activity in adolescents and adults with fibrodysplasia ossificans progressiva.</p><p>The companies said the US Food and Drug Administration has accepted the new drug application and granted priority review for zilurgisertib as a treatment for fibrodysplasia ossificans progressiva in patients 12 years and older.</p><p>The Prescription Drug User Fee Act target date for the product is Sept. 26, according to the companies.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2643275959","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643275959","pubTimestamp":1781510444,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mirum Pharmaceuticals  and Incyte  said Sunday their threapeutic candidate for fibrodysplasia ossificans progressiva, zilurgisertib, demonstrated positive results during a phase 2 study.The product showed meaningful reductions in total heterotopic ossification, or HO, lesion volume and no new HO lesions and flare activity in adolescents and adults with fibrodysplasia ossificans progressiva.The companies said the US Food and Drug Administration has accepted the new drug application and granted priority review for zilurgisertib as a treatment for fibrodysplasia ossificans progressiva in patients 12 years and older.The Prescription Drug User Fee Act target date for the product is Sept. 26, according to the companies.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","MIRM":"Mirum Pharmaceuticals, Inc.","BK4550":"红杉资本持仓","INCY":"因塞特医疗","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4532":"文艺复兴科技持仓"},"translate_title":"Mirum Pharmaceuticals和Incyte表示，Zilurgisertib在临床试验期间显示出异位骨化病变体积的显着减少","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1.5,"MIRM":1},"content_text":"Mirum Pharmaceuticals (MIRM) and Incyte (INCY) said Sunday their threapeutic candidate for fibrodysplasia ossificans progressiva, zilurgisertib, demonstrated positive results during a phase 2 study.The product showed meaningful reductions in total heterotopic ossification, or HO, lesion volume and no new HO lesions and flare activity in adolescents and adults with fibrodysplasia ossificans progressiva.The companies said the US Food and Drug Administration has accepted the new drug application and granted priority review for zilurgisertib as a treatment for fibrodysplasia ossificans progressiva in patients 12 years and older.The Prescription Drug User Fee Act target date for the product is Sept. 26, according to the companies.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}